Pure Global AI
NCT06368960Recruiting

BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors

The Study to Evaluate the Safety, PK, and Preliminary Efficacy of BM201 Injection Combined With Radiotherapy in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors That Failed Standard Therapy
InnoBM Pharmaceuticals Co., Ltd.Phase 1ClinicalTrials.govradiation
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
Radiotherapy
Study type
Interventional
Intervention type
radiation
Sponsor & location
Primary sponsor
InnoBM Pharmaceuticals Co., Ltd.
Location
Nanjing, China
Timeline & enrollment
Phase
Phase 1
Start date
Nov 07, 2022
End date
Dec 31, 2024
Enrollment
36 participants
Primary outcome

DLT and MTD,Pharmacokinetic (PK) parameters,Number of patients with adverse events (AEs)

Summary

This is a non-randomized，open-label，controlled multi-center Phase Ⅰ study to evaluate
 tolerability, pharmacokinetics, and preliminary efficacy of BM201 injection in combination
 with radiotherapy in patients with histologically or cytologically confirmed unresectable
 locally advanced or metastatic solid tumors who have failed standard therapy or are unable to
 receive standard treatment.

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06368960
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06368960 through Pure Global AI's free database. This Phase 1 trial is sponsored by InnoBM Pharmaceuticals Co., Ltd. and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.